Caixin Global – Latest China News & Headlines

Home >


CX Tech is Caixin Global's real-time tech news portal, featuring 24-hour news, short-form analysis, and roundups from business and tech media in China.

Sohu Returns to Profit in First Quarter as Online Gaming Revenue Grows
Chinese Trucking Startup ForU Applies for Nasdaq Listing
Baidu Aims to Replace State-of-the-Art Self-Driving Tech With Launch of V2X System
Chinese Snack-Maker Shapes Up as a Spicy Hong Kong Offering
Fresh Funding Lifts Blockchain-Based Gaming Firm Animoca Into Unicorn Club
Foxconn Drives Deeper Into Car Manufacturing With Fisker Deal
Tesla Wannabe Xpeng Reports Shrinking Losses as Deliveries Explode
Tencent Brings in Nearly $500 Million From ‘Honor of Kings’ and ‘PUBG Mobile’ in April
U.S. Senate Advances Bill That Would Ban TikTok from Government Devices
WeRide Raises Fresh Capital as It Ponders How to Make Money Off Self-Driving Cars
China’s 2021 Smartphone Sales Surge Comes to an End in April
Trending in China: Weibo Turns On E-Bike Riders After Battery Explodes in Elevator
U.S. Senate Committee Presses Companies to Comply with Rule Designed to Limit Supply Sales to Huawei Receives Green Light to Run Autonomous Freight Business in Guangzhou
Trending in China: Stories of Young Survivors on 13th Anniversary of Wenchuan Earthquake
Internet Security Apps Called Out for Personal Data Abuse
Online Insurance Upstart Yuanbao Bags $156 Million in New Funding Works with Luminar to Build Lidar-Powered Sensing System for Driverless Cars
Self-Driving Truck Startup Plus Aims for U.S. Listing in SPAC Deal
Biotech Firm BeiGene Turns First Profit Since 2018 Hong Kong Listing
China Adds 148 Drugs to Its National Insurance List

By Liu Denghui, Wang Lijun and Tang Ziyi / Aug 21, 2019 04:00 PM / Society & Culture

Photo: VCG

Photo: VCG

China on Tuesday added 148 drugs to a list of medicines eligible for reimbursement under government-backed insurance plans, its latest move to ease the financial burden on Chinese patients.

The updated catalog, released by the National Healthcare Security Administration, includes 47 foreign drugs and 101 traditional Chinese medicines. Notable additions involve global names such as AstraZeneca’s Kombiglyze and Merck & Co’s Janumet, both treatments for diabetes.

Five of the medicines are for rare diseases, 36 for chronic diseases such as diabetes, and 38 for pediatric use.

At the same time, the authority removed 150 drugs from the reimbursable list, ones that have relatively lower clinical value or can be substituted with better alternatives, said Xiong Xianjun, director of the Medical Service Department at the insurance administration.

Read the full report on Caixin Global later today.

Contact reporter Tang Ziyi (

Share this article
Open WeChat and scan the QR code